Glioma is one of the most common primary intracranial tumors.Due to difficulty of early diagnosis,complicated anatomical location and high recurrence rate,it has a very poor prognosis,making it one of the most fatal malignant tumors.In recent years,with the development of second-generation sequencing technology,liquid biopsy characterized by reproducible and minimally invasive methods has shown promising applications in the early detection,drug resistance monitoring,target detection and prognostic prediction of glioma.However,liquid biopsy still faces several columns of challenges in the clinical application of glioma patients.Therefore,this paper will explore the progress of liquid biopsy and its biomarkers and its clinical application in glioma.
维普
万方数据
